Break it Down: Cash in the bag for Tryptamine Therapeutics
In this episode, host Fraser Palamara dissects the $6 million raising completed today by biotech company Tryptamine Therapeutics.
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
In this episode, host Fraser Palamara dissects the $6 million raising completed today by biotech company Tryptamine Therapeutics (ASX:TYP).
Money garnered from the placement, priced at 2c per share, will be used to accelerate the company's studies in psilocybin and psilocin IV dosing to therapeutically treat patients.
Tune in to get the latest.
While Tryptamine Therapeutics is a Stockhead advertiser, it did not sponsor this content.
Originally published as Break it Down: Cash in the bag for Tryptamine Therapeutics
QMines loads up for copper drilling
ASX junior QMines is ready to reap the rewards of a rising copper price as it restocks to explore its Mt Chalmers and Develin Creek projects.
When chasing dividends, don’t forget the growth story
While dividend yields are important for self-funded investors, they need to consider the prospects for capital gains as well.
Rio closes on $10bn Arcadium deal
Rio Tinto is placed to closed its transaction to acquire Arcadium Lithium next month after receiving all foreign investment approvals.